

Milan, Italy 10-12 October 2024

#### Welcome!

"CAR T-cell, Cellular Therapies and Immunology in Autoimmune Diseases"

To the 1st Joint Educational Meeting of the Autoimmune Diseases Working Party (ADWP) and the Cellular Therapy and Immunobiology Working Party (CTIWP) of the EBMT, which will be held on October 2024 in Milan, Italy.

The programme will cover all aspects of innovative cellular therapies, particularly CAR-T cells, in relation to the pathophysiology and therapy of autoimmune diseases, including current and future indications, immunological mechanisms and novel targets.

Moreover, current practical challenges, early and late complications, infections, technologies (eg. new CAR-T cell strategies) and area of unmet need in relation to transplant and conventional treatments will be widely covered in this context.

A multidisciplinary approach is key in this field, and this educational meeting will bring together most of the world's leading experts, actively contributing to the evidence base and professional guidelines in the field, who will present their most recent work and describe the expected developments in the near future. In keeping with the scientific and educational scope of the meeting, the meeting will give delegates & sponsors the chance to lively interact and network with experts in the field.

We are looking forward to welcoming you to this Educational Meeting in Milano, and we kindly invite you to submit scientific abstracts and/or case presentations to be actively discussed in the sessions or as posters.

Yours sincerely,

Tobias Alexander, Autoimmune Diseases WP Chair Raffaella Greco, Former Chair Autoimmune Diseases WP Chair and local organiser Elisa Roldangalvan, Autoimmune Diseases WP Secretary Annalisa Ruggeri, Cellular Therapies and Immunology WP Chair and local organiser Jürgen Kuball, Cellular Therapies and Immunology WP Vice-chair Florent Malard, Cellular Therapies and Immunology WP Secretary

Milan, Italy 10-12 October 2024

#### Thursday, 10 October 2024

10:00 - 12:00	Autoimmune Diseases & Cellular Therapy and Immunobiology WP Scientif Open for everybody	ases & Cellular Therapy and Immunobiology WP Scientific Business Meetings	
12:45 – 13:45	Joint Autoimmune Diseases & Cellular Therapy and Immunobiology WP So Open for everybody	ientific Business Meeting	
14:00 – 15:00	Session I: Current EBMT indications		
	Chairs: Annalisa Ruggeri (IT) & Raffaella Greco (IT)		
14:00 – 14:20	CART cells: standard indications and EBMT registry	Annalisa Ruggeri (IT)	
14:20 – 14:40	EBMT Recommendations for autoimmune diseases undergoing CART cells	Raffaella Greco (IT)	
14:40 – 15:00	EBMT standard indications for HSCT in autoimmune diseases	John Snowden (UK)	
15:00 – 16:30	Session II: Pathophysiology and novel therapeutic targets		
	Chairs: Florent Malard (FR) & Tobias Alexander (DE)		
15:00 – 15:20	Rheumatic and musculoskeletal diseases	Hans Ulrich Scherer (NL)	
15:20 – 15:40	Neurological autoimmune diseases	Paolo Muraro (UK)	
15:40 - 16:00	Microbiome	Florent Malard (FR)	
16:00 – 16:10	Case presentation: Refractory Myasthenia Gravis Treated with		
	Autologous Hematopoietic Cell Transplantation	Jan Storek (CA)	
16:10 - 16:20	Case presentation: Myelopathy after CAR T therapy:		
	acute and delayed neurotoxicity	Carolina Rush (CA)	
16:20 - 16:30	Case presentation: Anti-CD19 chimeric antigen receptor T cell therapy		
	successfully depletes B cells in the peripheral blood and lymphatic		
	organs of a patient with systemic lupus erythematosus	Ioanna Minopoulou (DE)	
16:30 – 17:00	Coffee Break		
17:00 – 17:45	Keynote lecture		
	Chairs: Jürgen Kuball (NL) & Katharina Fleischhauer (DE)		
	Challenges in Cell Therapy: TCR & CART	Chiara Bonini (IT)	

EBMT



Milan, Italy 10-12 October 2024

		Friday, 11 October 2024	
09:00 - 10:00	Session III: Immunology Chairs: Simona Pagliuca (FR) & Hans Ulrich Scherer (NL)		
09:00 - 09:20	Immune monitoring post HSCT	Elena Tassi (IT)	
09:20 - 09:40	Immune monitoring post CART	Simona Pagliuca (FR)	
09:40 - 10:00	GoCART update	Jürgen Kuball (NL)	
10:00 – 10:45	Industry Symposium "CAR T cell therapy in autoimmune diseases – clinical experience with		
10:00 - 10:05	KYV-101" by Kyverna Welcome and Introductions	Dominic Borie (US)	
10:05 - 10:05	Early Experiences with Anti-CD19 CAR T-Cell Therapies in Autoimmune Diseases	Dimitrios Mougiakakos (DE)	
10:20 - 10:30	Perspectives on CAR T-Cell Therapy in Autoimmune Diseases	Raffaella Greco (IT)	
10:30 – 10:45	Case Presentations of CAR T-Cells in Neurologic Autoimmune Diseases	Aiden Haghikia (DE)	
10:45 – 11:15	Coffee Break		
11:15 – 12:55	Session IV: Controversies in Cellular Therapies (part I) Chairs: Nicoletta del Papa (IT) & Annalisa Ruggeri (IT)		
11:15 – 11:55	Systemic Lupus Erythematosus		
11:15 – 11:25	Standard treatment	Luca Moroni (IT)	
11:25 – 11:35	HSCT	Tobias Alexander (DE)	
11:35 – 11:45	CART cells	Tobias Alexander (DE)	
11:45 - 11:55	Round table discussion		
12:05 - 12:55	Systemic Sclerosis/Myositis Standard treatment	Marco Matucci (IT)	
12:05 – 12:15 12:15 – 12:25	HSCT	Nicoletta del Papa (IT)	
12:25 - 12:35	CART cells in Systemic Sclerosis	Christina Bergmann (DE)	
12:35 - 12:45	CART cells in myositis	Jörg Henes (DE)	
12:45 - 12:55	Round table discussion		
12:55 – 14:00	Lunch Break		
14:00 – 15:40	Session IV: Controversies in Cellular Therapies (part II)		
	Chair: Paolo Muraro (UK) & Massimo Filippi (IT)		
14:00 – 14:40	Multiple Sclerosis		
14:00 - 14:10	Standard treatments in Multiple Sclerosis	Sara Gil-Perotín (SP)	
14:10 – 14:20 14:20 – 14:30	HSCT in Multiple Sclerosis CART in Multiple Sclerosis	Matilde Inglese (IT) Chris Heesen (DE)	
14:30 - 14:40	Round table discussion	Chills Heesen (DL)	
14:50 - 15:40	Rare neurologic indications		
14:50 - 15:00	Standard treatments in Neuromyelitis Optica	Lucia Moiola (IT)	
15:00 - 15:10	HSCT in Neuromyelitis Optica and Myasthenia Gravis	Basil Sharrack (UK)	
15:10 – 15:20	CART cells in Neuromyelitis Optica	Wei Wang (CN)	
15:20 – 15:30	CART cells in Myasthenia Gravis	Aiden Haghikia (DE)	
15:30 – 15:40	Round table discussion		
15:40 – 16:10	Coffee Break		
16:10 – 17:20	Session V: Novel CAR technologies and indications		
16:10 - 16:25	<b>Chair:</b> <i>Matteo Doglio (IT) &amp; Vanderson Rocha (BR)</i> Heterogeneity & efficacy of different engineered T cells	Jürgen Kuball (NL)	
16:25 - 16:40	Increasing access of CAR T cell in Brazil	Vanderson Rocha (BR)	
16:40 - 16:55	"Off-the-Shelf" Allogeneic CART: how to overcome GvH and host allorejection	Eolia Brissot (FR)	
16:55 – 17:10	CAR Tregs in autoimmunity	Matteo Doglio (IT)	
17:10 – 17:20	Case presentation: CAR T therapy for poly-refractory seropositive		
	rheumatoid arthritis	Doron Rimar (IL)	

EBMT

Milan, Italy 10-12 October 2024

		Saturday, 12 October 2024
08:30 – 09:00	<b>Special lecture in memory of Riccardo Saccardi</b> <b>Chairs:</b> Raffaella Greco (IT) & Annalisa Ruggeri (IT) The long journey of HSCT in Multiple Sclerosis: from biology to clinical setting	Paolo Muraro (UK)
09:00 – 10:00	Session VI: CART cell toxicities Chair: Ana Alarcón (SP) & Basil Sharrack (UK)	
09:00 – 09:20 09:20 – 09:40	Cytokine Release Syndrome and Neurologic Toxicities for CART (incl. case) CART kinetics in PB/CSF for MS patients: correlation with	Ana Alarcón (SP)
09:40 – 10:00	outcome and toxicities Toxicity profile of CART cells in ADs	Johanna Richter (DE) Fabian Müller (DE)
10:00 – 10:45	Industry Symposium "CAR T Cell Therapy: Bringing a Decade of Experience Diseases" by Bristol Myers Squibb	to Patients with Autoimmune
10:00 – 10:05 10:05 – 10:20 10:20 – 10:40 10:40 – 10:45	Introduction Optimizing CAR T Cell Therapy: Challenges and Opportunities Future perspectives of CAR-T Summary and Q&A	Reuben Benjamin (UK) Reuben Benjamin (UK) Melanie Hagen (DE)
10:45 – 11:15	Coffee Break	
11:15 – 12:15	Session VII: Late complications after cellular therapies Chairs: John Snowden (UK) & Johanna Richter (DE)	
11:15 – 11:35 11:35 – 11:55	Autoimmune complications post allo-HSCT Secondary malignancies after CART cells	Arsene Mekinian (FR) Fabio Ciceri (IT)
11:55 – 12:55	Session VIII: Other cellular therapeutic approaches Chairs: Rosamaria Nitti (IT) & Tobias Alexander (DE)	
11:55 – 12:15	Neural stem cells	Angela Genchi (IT)
12:15 – 12:35	Mesenchymal stromal cells	Dominique Farge (FR)
12:35 – 12:55	Induced pluripotent stem cells	Richard Burt (US)
12:55 – 13:00	Take-home messages from all the organizers	

EBMT



Milan, Italy 10-12 October 2024

#### SPECIAL THANKS TO OUR SPONSORS

INDUSTRY SYMPOSIUM



# **H** Bristol Myers Squibb<sup>®</sup>

SILVER PARTNER

